Received Jul 7, 2026
Reports are unverified and do not show that a vaccine caused an event. Full disclaimer
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNP | MENINGOCOCCAL CONJUGATE (PENMENVY) | GLAXOSMITHKLINE BIOLOGICALS | UNK | CB25N | — |
Penmenvy liquid only administration; Penmenvy liquid only administration; This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate preparation of medication in a 16-year-old male patient who received Men ABCWY NVS (Penmenvy) suspension for injection in pre-filled syringe (batch number CB25N with expiry date 07-JAN-2027) for prophylaxis. On 01-JUL-2026, the patient received Penmenvy. On 01-JUL-2026, an unknown time after receiving Penmenvy, the patient experienced inappropriate preparation of medication (Verbatim: Penmenvy liquid only administration) and inappropriate dose of vaccine administered (Verbatim: Penmenvy liquid only administration). The outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 01-JUL-2026 The reporter stated that the provider had wanted to know how to proceed with a patient who had received only the diluent (MenB component) of Penmenvy without it being reconstituted, and whether the dose counted as valid.